Clinical Trial Update: CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma

View source ↗

Summary

The clinical trial update reports cardiac toxicity concerns linked to immunotherapy for melanoma and indicates ongoing safety monitoring for participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Melanoma Stage III or IV | Status: ENROLLING_BY_INVITATION